Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
32729368
Public Release Type:
Journal
Publication Year: 2020
DOI:
https://doi.org/10.1080/14728214.2020.1803276
Authors:
Trachtman Howard
Request IDs:
21203
Studies:
FONT 2 Study: Novel Therapies for Resistant FSGS Phase II Clinical Trials
Glomerulosclerosis represents the final stage of glomerular injury during the course of kidney disease and can represent a primary disturbance in disorders like focal segmental glomerulosclerosis or a secondary response to tubulointerstitial disease. Overall, primary focal glomerulosclerosis (FSGS), the focus of this review, accounts for 10–20% of patients of all ages who progress to end stage kidney disease. There are no FDA approved therapeutic options that effectively prevent or delay the onset of kidney failure.
